Last updated: February 22, 2026
What Is NDC 20482-0012?
NDC 20482-0012 refers to Spravato (Esketamine) nasal spray, developed by Johnson & Johnson. It is approved for treatment-resistant depression (TRD) and major depressive disorder with acute suicidal ideation or behavior.
Market Size and Growth
Current Market Landscape
- Marketed since: March 2019.
- Primary indications: Treatment-resistant depression (TRD), depression with suicidality.
- Competitive products: Brexanolone (Zulresso), ketamine clinics, traditional antidepressants.
Market Size
- Global antidepressant market: Estimated at USD 16 billion in 2022 (~USD 18 billion projected for 2025).[1]
- Nasal ketamine and esketamine segment: Accounts for approximately USD 2 billion in sales globally (2022).
- U.S. market share: Approximately 70-80% of esketamine sales occur domestically, driven by FDA approval and insurance coverage.
Growth Drivers
- Increasing prevalence of depression (over 300 million globally).
- Rising adoption of rapid-acting antidepressants.
- Expanding indications beyond TRD to include major depressive disorders with suicidality.
- Reimbursement approvals expanding access via insurers and Medicaid.
Market Challenges
- High treatment costs.
- Strict administration protocols (due to risks of sedation and abuse).
- Limited provider familiarity outside specialty clinics.
- Pricing controversies, potential price caps.
Market Projection (2023–2028)
| Year |
Estimated Global Market (USD Billion) |
Growth Rate (%) |
| 2023 |
2.2 |
10 |
| 2024 |
2.42 |
10 |
| 2025 |
2.66 |
10 |
| 2026 |
2.92 |
10 |
| 2027 |
3.21 |
10 |
| 2028 |
3.53 |
10 |
This projection assumes steady growth driven by expanding indications and increasing awareness.
Pricing Overview and Projections
Current Pricing Landscape
- Per-dose price (U.S. retail): Approximately USD 590–USD 650.
- Course of treatment: Typically involves two initial doses weekly for four weeks, then maintenance doses, leading to total costs of USD 5,000–USD 10,000+ per patient annually.
- Insurance coverage: Widely available but with prior authorization requirements restrict access for some patients.
Price Trends
- Price inflation has been minimal (+2–3%) annually, influenced by manufacturing costs and reimbursement pressures.
- Attempts at price reductions or tiered pricing models are underway by some payers to lower out-of-pocket costs.
Future Price Projections
| Year |
Estimated Per-Unit Cost (USD) |
Justification |
| 2023 |
650 |
Current pricing stabilized by market competition and reimbursement negotiations. |
| 2024 |
670 |
Slight increase due to inflation and expanded label indications. |
| 2025 |
690 |
Potential price pressure from biosimilar or generic development phases. |
| 2026 |
700 |
Cost adjustments driven by manufacturing efficiencies. |
| 2027 |
720 |
Slight upward pressure due to demand and limited competition. |
Factors Influencing Future Pricing
- Entry of biosimilars or generics could pressure prices downward.
- Expanded indications may justify higher prices due to increased value.
- Policy measures targeting drug pricing could cap costs.
Competitive and Regulatory Outlook
Competitive Products
| Product |
Status |
Price Comparison |
Indications |
| Brexanolone (Zulresso) |
Approved for postpartum depression |
Similar high-cost profile |
Postpartum depression |
| Traditional ketamine |
Off-label use |
Lower (USD 300–USD 500 per dose) |
TRD, off-label use |
| Generic ketamine |
Available for off-label use |
USD 100–USD 300 |
TRD, anesthesia |
Regulatory Risks
- Future FDA or international agency pricing restrictions.
- Possible re-evaluation of abuse potential regulations.
- Legislation favoring biosimilars or cheaper alternatives.
Summary
NDC 20482-0012 (Spravato) exhibits a growing market segment driven by unmet needs in depression treatment. Current pricing stays around USD 600 per dose, with modest inflation projections. The anticipated market expansion hinges on increased adoption, reimbursement policy adjustments, and competitive pressures from biosimilars.
Key Takeaways
- Market projected to grow at 10% annually, reaching USD 3.5 billion globally by 2028.
- Treatment costs average USD 5,000–USD 10,000 annually, with stable per-dose pricing expected.
- Competition from generic ketamine and biosimilars could impact future pricing.
- Positive reimbursement trends support market stability but heighten regulatory risk.
- Expanded indications and clinical acceptance will be key to sustained growth.
FAQs
Q1: What factors could threaten the price stability of NDC 20482-0012?
A: Introduction of biosimilars, regulatory price caps, and shifts in reimbursement policies.
Q2: How does the cost of esketamine compare to off-label ketamine use?
A: Esketamine costs about USD 600 per dose, whereas off-label ketamine is USD 300–USD 500 per dose, with less regulatory oversight.
Q3: What is the primary driver of growth in the esketamine market?
A: Increasing prevalence of treatment-resistant depression and expansion of approved indications.
Q4: Are insurance reimbursements sufficient to support ongoing market growth?
A: Yes, but coverage varies, and prior authorization remains a barrier for some patients.
Q5: What policies could influence future market dynamics?
A: Price regulation, approval of biosimilars, and increased oversight of abuse potential.
References
[1] IQVIA. (2022). Global Pharmaceutical Market Report.
